Robert Eugene Kristal - 13 Feb 2024 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
Chief Financial Officer
Signature
/s/ Robert Kristal
Issuer symbol
BRTX
Transactions as of
13 Feb 2024
Net transactions value
$0
Form type
4
Filing time
15 Feb 2024, 16:17:05 UTC
Previous filing
17 Feb 2023
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 7,994 13 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Award $0 +263,158 $0.000000 263,158 13 Feb 2024 Common Stock 263,158 $1.45 Direct F3
holding BRTX Stock Option 10,490 13 Feb 2024 Common Stock 10,490 $5.08 Direct F1
holding BRTX Stock Option 88,968 13 Feb 2024 Common Stock 88,968 $2.91 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is currently exercisable.
F2 The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 131,579 shares on February 13, 2024 with the remaining 131,579 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested.